FDA will issue a Complete Response Letter for MDMA-PTSD NDA by September 30, 2026, requiring additional long-term safety data rather than granting approval or outright rejection

The FDA's advisory committee voted against approving MDMA (the active ingredient in Ecstasy) for PTSD in June 2024, citing concerns about trial design flaws and whether patients' function really improved. Rather than simply rejecting the application, the FDA will most likely issue a Complete Response Letter — a formal request for more data. This is the safest middle ground: it avoids the political fallout of approving a Schedule I drug while also avoiding the optics of rejecting a potential PTSD treatment supported by veterans' groups.

The FDA AdCom voted against approval in June 2024 citing unblinding, functional impairment data, and abuse liability concerns. Congressional scrutiny via the Taxpayer Funds Act creates institutional incentive for caution. A CRL demanding further data is the path of least resistance: it avoids the political cost of approving a Schedule I substance with contested trial integrity while also avoiding the optics of outright rejection of a PTSD treatment with veteran advocacy support. No new clinical data package has been submitted that would resolve the AdCom's core objections before the resolution date.